NVDA
NVIDIA
-- 114.060 TSLA
Tesla
-- 284.650 TSM
Taiwan Semiconductor
-- 172.970 PLTR
Palantir
-- 83.420 AMD
Advanced Micro Devices
-- 98.230 
NEWS
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, with 81% in ESR1 mutation patients and 70% in ESR1 wild-type patients.
The Phase 1b/2 study included 62 patients, with 56 receiving the recommended Phase 2 dose. The combination demonstrated favorable tolerability and safety profile consistent with ribociclib and endocrine therapy. Notable outcomes include a 76% clinical benefit rate across all patients and 27% objective response rate in patients with measurable disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
104079172 : I attended the pre-symposium analyst presentation of just now and the results of the current 6 month in phase trial for Olema's palazestrant is extremely promising pre the big upcoming trial in 2025